Associations of Atrial Fibrillation Patterns With Mortality and Cardiovascular Events: Implications of the MISOAC-AF Trial [0.03%]
心房颤动模式与死亡率和心血管事件的关系：MISOAC-AF试验的启示
Amalia Baroutidou,Anastasios Kartas,Athanasios Samaras et al.
Amalia Baroutidou et al.
Aim: This retrospective cohort study aimed to evaluate the prognostic implications of the distinct atrial fibrillation (AF) temporal patterns: first diagnosed, paroxysmal, and persistent or permanent AF. ...
Wasim S El Nekidy,Khalid Almuti,Hazem ElRefaei et al.
Wasim S El Nekidy et al.
Background: Several reports linked the use of repurposed drugs such as hydroxychloroquine (HCQ), azithromycin, lopinavir/ritonavir, and favipiravir with QT interval prolongation in patients with SARS-CoV2 infection. Littl...
The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A Review [0.03%]
心力衰竭患者的血管紧张素受体脑啡肽酶抑制剂疗效和安全性评估：综述文章
Rui Zhang,Xiaotong Sun,Ya Li et al.
Rui Zhang et al.
Heart failure (HF) is one of the leading causes of morbidity and mortality worldwide. Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has been approved for the treatment of HF. At present, there have been few systematic ...
IV Sodium Ferric Gluconate Complex in Patients Hospitalized Due to Acute Decompensated Heart Failure and Iron Deficiency [0.03%]
急性心力衰竭失代偿伴铁缺乏患者使用葡萄糖酸亚铁复合物注射液的研究
Itay Borreda,Robert Zukermann,Danny Epstein et al.
Itay Borreda et al.
Background: Patients suffering from heart failure (HF) and iron deficiency (ID) have worse outcomes. Treatment with intra-venous (IV) ferric carboxymaltose has been shown to reduce HF rehospitalizations and to improve functional capacity an...
Gender Related Differences in Gastrointestinal Bleeding With Oral Anticoagulation in Atrial Fibrillation [0.03%]
房颤口服抗凝血治疗的胃肠出血性别差异分析
Eliana Ferroni,Gentian Denas,Nicola Gennaro et al.
Eliana Ferroni et al.
Background: DOACs are characterized by a higher incidence of gastrointestinal bleeding and this may be different among males and females. Female patients were underrepresented in the DOAC pivotal trials. We aimed to assess real-world differ...
Impact of Homoarginine on Myocardial Function and Remodeling in a Rat Model of Chronic Renal Failure [0.03%]
组氨酸对慢性肾衰竭大鼠心肌功能及重塑的影响
Vitali Koch,Christophe Weber,Johannes H Riffel et al.
Vitali Koch et al.
Purpose: Low plasma concentrations of the amino acid homoarginine (HA) have been shown to correlate with adverse cardiovascular outcome, particularly in patients with chronic kidney disease. The present study sought to in...
Hydrochlorothiazide Reduces Cardiac Hypertrophy, Fibrosis and Rho-Kinase Activation in DOCA-Salt Induced Hypertension [0.03%]
氢氯噻嗪降低DOCA-盐引起高血压心脏肥大，纤维化和Rho激酶激活
David Mondaca-Ruff,Patricio Araos,Cristián E Yañez et al.
David Mondaca-Ruff et al.
Background: Thiazides are one of the most common antihypertensive drugs used for hypertension treatment and hydrochlorothiazide (HCTZ) is the most frequently used diuretic for hypertension treatment. The Rho/Rho-kinase (R...
Factors Influencing the Selection of Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Non-Valvular Atrial Fibrillation [0.03%]
非瓣膜性房颤患者卒中预防选择非维生素K拮抗剂口服抗凝药的影响因素
Susin Park,Nam Kyung Je
Susin Park
Background: Major atrial fibrillation (AF) guidelines recommend non-vitamin K antagonist oral anticoagulants (NOACs) over warfarin, except in rare clinical circumstances based on 4 randomized controlled trials comparing e...
The β3 Adrenergic Receptor Antagonist L-748,337 Attenuates Dobutamine-Induced Cardiac Inefficiency While Preserving Inotropy in Anesthetized Pigs [0.03%]
β3肾上腺素能受体拮抗剂L-748，337减轻多巴胺诱导的心脏功能障碍同时在麻醉猪中维持肌力变化
Lars Rødland,Leif Rønning,Anders Benjamin Kildal et al.
Lars Rødland et al.
Excessive myocardial oxygen consumption (MVO2) is considered a limitation for catecholamines, termed oxygen cost of contractility. We hypothesize that increased MVO2 induced by dobutamine is not directly related to contractility but linked ...
Absent or Mild Coronary Calcium Predicts Low-Risk Stress Test Results and Outcomes in Patients Considered for Flecainide Therapy [0.03%]
冠状钙的缺失或轻微存在预示着在考虑使用氟卡尼治疗患者时压力测试结果和结局的良好风险程度
Jeffrey L Anderson,Stacey Knight,Raymond O McCubrey et al.
Jeffrey L Anderson et al.
Background: Flecainide is a useful antiarrhythmic for atrial fibrillation (AF). However, because of ventricular proarrhythmia risk, a history of myocardial infarction (MI) or coronary artery disease (CAD) is a flecainide ...